Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Preferred Shares (2017 - 2021)

Historic Preferred Shares for Avalo Therapeutics (AVTX) over the last 5 years, with Q1 2021 value amounting to $1000.0.

  • Avalo Therapeutics' Preferred Shares fell 2044.55% to $1000.0 in Q1 2021 from the same period last year, while for Mar 2021 it was $1000.0, marking a year-over-year decrease of 2044.55%. This contributed to the annual value of $1000.0 for FY2020, which is 6499.82% down from last year.
  • Per Avalo Therapeutics' latest filing, its Preferred Shares stood at $1000.0 for Q1 2021, which was down 2044.55% from $1000.0 recorded in Q4 2020.
  • In the past 5 years, Avalo Therapeutics' Preferred Shares ranged from a high of $2857.0 in Q4 2018 and a low of $4.0 during Q1 2017
  • Moreover, its 5-year median value for Preferred Shares was $1257.0 (2020), whereas its average is $1672.0.
  • In the last 5 years, Avalo Therapeutics' Preferred Shares changed by 0.0% in 2019 and then plummeted by 6499.82% in 2020.
  • Over the past 5 years, Avalo Therapeutics' Preferred Shares (Quarter) stood at $4.0 in 2017, then skyrocketed by 71325.0% to $2857.0 in 2018, then changed by 0.0% to $2857.0 in 2019, then crashed by 65.0% to $1000.0 in 2020, then changed by 0.0% to $1000.0 in 2021.
  • Its last three reported values are $1000.0 in Q1 2021, $1000.0 for Q4 2020, and $1257.0 during Q3 2020.